44 related articles for article (PubMed ID: 23489237)
1. Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim.
Marchesi F; Terrenato I; Papa E; Tomassi M; Falcucci P; Gumenyuk S; Palombi F; Pisani F; Renzi D; Romano A; Spadea A; Regazzo G; Rizzo MG; De Rienzo M; Ripellino C; Sgromo S; Viggiani C; Ponte E; Kayal R; Cordone I; Foddai ML; Mengarelli A
Ann Hematol; 2024 Mar; 103(3):947-956. PubMed ID: 38189833
[TBL] [Abstract][Full Text] [Related]
2. Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation.
Eplin DD; Jackson AD; Smith AM; Salvig B; Chinratanalab W; Savani BN
Clin Hematol Int; 2019 Dec; 1(4):229-233. PubMed ID: 34595434
[TBL] [Abstract][Full Text] [Related]
3. Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis.
Gardellini A; Gigli F; Babic A; Andreola G; Radice D; Sammassimo S; Martinelli G; Laszlo D
Ecancermedicalscience; 2013; 7():327. PubMed ID: 23818939
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic stem cell apheresis in the context of a related allogeneic transplant for acute myeloid leukemia: an unexpected outcome, medical emergency and ethical issue.
Bourgeois M; Sonet A; Botson F; Graux C; Fabry A; André M; Deneys V
Haematologica; 2017 Mar; 102(3):e115-e116. PubMed ID: 27927773
[No Abstract] [Full Text] [Related]
5. The impact of diabetes mellitus on hematopoietic stem cell mobilization, a-single center cohort study.
Çelik S; Kaynar L; Güven ZT; Begendi NK; Demir F; Keklik M; Ünal A
Transfus Apher Sci; 2023 Dec; 62(6):103838. PubMed ID: 37925340
[TBL] [Abstract][Full Text] [Related]
6. Ethical issues and concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilisation of stem cells in normal donors.
Liumbruno GM; Petrini C
Blood Transfus; 2012 Oct; 10(4):550-2. PubMed ID: 22507862
[No Abstract] [Full Text] [Related]
7. Forensic sequencing of Salmonella cultured from hematopoietic progenitor cell products collected by apheresis from two asymptomatic donors.
Koepsell S
Transfusion; 2023 Aug; 63(8):1615-1617. PubMed ID: 37563840
[No Abstract] [Full Text] [Related]
8. A global assessment of hemostatic function of healthy allogeneic stem cell donors undergoing apheresis by rotational thromboelastometry.
Cilek N; Ugurel E; Eren OC; Yalcin O; Akay OM
Ther Apher Dial; 2024 Mar; ():. PubMed ID: 38462734
[TBL] [Abstract][Full Text] [Related]
9. Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network.
Marchesi F; Cerchiara E; Dessanti ML; Gumenyuk S; Franceschini L; Palombi F; Pisani F; Romano A; Spadea A; Pupo L; Annibali O; La Malfa A; Arcese W; Mengarelli A
Br J Haematol; 2015 Apr; 169(2):293-6. PubMed ID: 25371286
[No Abstract] [Full Text] [Related]
10. Biosimilars: the science of extrapolation.
Weise M; Kurki P; Wolff-Holz E; Bielsky MC; Schneider CK
Blood; 2014 Nov; 124(22):3191-6. PubMed ID: 25298038
[TBL] [Abstract][Full Text] [Related]
11. G-CSF: filgrastim, lenograstim and biosimilars.
Welte K
Expert Opin Biol Ther; 2014 Jul; 14(7):983-93. PubMed ID: 24707817
[TBL] [Abstract][Full Text] [Related]
12. Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation.
Schmitt M; Publicover A; Orchard KH; Görlach M; Wang L; Schmitt A; Mani J; Tsirigotis P; Kuriakose R; Nagler A
Theranostics; 2014; 4(3):280-9. PubMed ID: 24505236
[TBL] [Abstract][Full Text] [Related]
13. Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant.
Uddin S; Russell P; Farrell M; Davy B; Taylor J; Agrawal SG
Ther Adv Hematol; 2015 Apr; 6(2):53-60. PubMed ID: 25830013
[TBL] [Abstract][Full Text] [Related]
14. Lenograstim compared to filgrastim for the mobilization of hematopoietic stem cells in healthy donors.
Pérez-López O; Martín-Sánchez J; Parody-Porras R; Espigado-Tocino I; Noguerol P; Carmona-González M; Pérez-Simón JA
Transfusion; 2013 Dec; 53(12):3240-2. PubMed ID: 23489237
[TBL] [Abstract][Full Text] [Related]
15. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
16. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
